Banque Cantonale Vaudoise Buys New Shares in Humana Inc. (NYSE:HUM)

Banque Cantonale Vaudoise purchased a new stake in Humana Inc. (NYSE:HUM) during the first quarter, HoldingsChannel.com reports. The fund purchased 8,721 shares of the insurance provider’s stock, valued at approximately $2,308,000.

Several other large investors also recently bought and sold shares of the stock. Revolve Wealth Partners LLC purchased a new stake in shares of Humana during the fourth quarter worth approximately $202,000. American Century Companies Inc. boosted its position in Humana by 8.8% during the fourth quarter. American Century Companies Inc. now owns 12,655 shares of the insurance provider’s stock worth $3,211,000 after purchasing an additional 1,027 shares in the last quarter. Pictet Asset Management Holding SA increased its position in shares of Humana by 18.8% in the fourth quarter. Pictet Asset Management Holding SA now owns 72,803 shares of the insurance provider’s stock valued at $18,471,000 after buying an additional 11,523 shares in the last quarter. Orion Portfolio Solutions LLC grew its position in shares of Humana by 3.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider’s stock valued at $1,226,000 after purchasing an additional 171 shares during the last quarter. Finally, Allstate Corp purchased a new stake in shares of Humana during the fourth quarter worth about $905,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

Humana stock opened at $232.59 on Wednesday. The stock’s fifty day moving average price is $233.79 and its two-hundred day moving average price is $255.68. The firm has a market cap of $28.07 billion, a PE ratio of 16.45, a price-to-earnings-growth ratio of 1.58 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. Humana Inc. has a one year low of $206.87 and a one year high of $406.09.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm posted $7.23 EPS. As a group, research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Barclays set a $268.00 price objective on shares of Humana and gave the company an “equal weight” rating in a research note on Thursday, June 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Mizuho increased their price objective on Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research report on Wednesday, April 9th. Truist Financial reduced their price objective on Humana from $280.00 to $260.00 and set a “hold” rating for the company in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company set a $348.00 price target on Humana in a research report on Friday, July 18th. Sixteen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $282.43.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.